Treatment of Compensated Cirrhosis from Hepatitis C
For patients with compensated (Child-Pugh A) cirrhosis from hepatitis C, the treatment of choice is either sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks for most genotypes, with genotype 3 requiring intensified therapy. 1
Treatment-Naïve Patients with Compensated Cirrhosis
Genotypes 1a, 1b, 2,4,5, or 6
Two equally effective first-line options exist:
- Sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks achieves SVR12 rates >95% 1, 2
- Glecaprevir/pibrentasvir once daily for 8 weeks also achieves SVR12 rates >95% 1, 2
Both regimens are pangenotypic and carry A1-level evidence from EASL guidelines, meaning they are strongly recommended based on high-quality data. 1 The choice between these two can be based on treatment duration preference (8 vs 12 weeks), cost, and drug availability. 2
Genotype 3 with Compensated Cirrhosis (More Challenging)
Genotype 3 requires intensified therapy because dual-DAA regimens alone have higher failure rates. 1, 2 Three equally effective options exist:
- Sofosbuvir/velpatasvir + weight-based ribavirin (1,000 mg if <75 kg; 1,200 mg if ≥75 kg) for 12 weeks 1, 2
- Sofosbuvir/velpatasvir/voxilaprevir (triple-DAA) for 12 weeks 1, 2
- Glecaprevir/pibrentasvir for 12 weeks 1, 2
If baseline NS5A resistance testing reveals the Y93H resistance-associated substitution, you must use either sofosbuvir/velpatasvir plus ribavirin or sofosbuvir/velpatasvir/voxilaprevir. 1, 2 Patients without the Y93H mutation can receive sofosbuvir/velpatasvir alone for 12 weeks. 1
Treatment-Experienced Patients with Compensated Cirrhosis
Genotypes 1a, 1b, 2,4,5, or 6
- Sofosbuvir/velpatasvir for 12 weeks 1, 2
- Glecaprevir/pibrentasvir for 12 weeks (note the extended duration from 8 to 12 weeks in treatment-experienced patients) 1, 2
Genotype 3 with Compensated Cirrhosis
Treatment-experienced genotype 3 patients with compensated cirrhosis require even more aggressive therapy:
- Sofosbuvir/velpatasvir + weight-based ribavirin (1,000 mg if <75 kg; 1,200 mg if ≥75 kg) for 12 weeks 1, 2
- Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks 1, 2
- Glecaprevir/pibrentasvir for 16 weeks (note the extended duration to 16 weeks in treatment-experienced patients) 1, 2
Pre-Treatment Evaluation
Before initiating therapy, you must:
- Confirm active HCV replication with quantitative HCV RNA testing to establish baseline viral load 2, 3
- Determine Child-Pugh classification to confirm compensated (Class A) status 1
- Identify the genotype if the patient is treatment-experienced or has genotype 3 with cirrhosis, as this determines regimen selection and duration 2
- Screen for hepatitis B and HIV coinfection because they accelerate fibrosis progression and alter management 2
- Review all concomitant medications to identify and manage drug-drug interactions 2
Genotyping is NOT required for treatment-naïve patients with genotypes 1,2,4,5, or 6 when using pangenotypic regimens. 2 However, genotype 3 patients with cirrhosis require genotyping to select appropriate intensified therapy. 2
Critical Pitfalls to Avoid
Do not use protease inhibitor-containing regimens (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir) if the patient has any history of decompensation, even if they are currently Child-Pugh A. 1, 2 These drugs cause substantially higher drug exposure and risk of hepatotoxicity in patients with prior decompensation. 1
Do not undertreat genotype 3 with compensated cirrhosis by using sofosbuvir/velpatasvir alone without ribavirin or a third agent. 1, 2 Genotype 3 has intrinsically higher resistance rates and requires intensified therapy to achieve optimal cure rates. 2
Do not delay treatment in patients with ongoing substance use or alcohol consumption. 2 Active injection drug use is not a contraindication to DAA therapy if adherence can be ensured, and adherent patients achieve comparable cure rates to abstinent patients. 2
Expected Outcomes and Prognosis
Achieving sustained virologic response (SVR) in compensated cirrhosis halts disease progression, induces regression of fibrosis in more than half of patients, reduces the need for liver transplantation, and improves survival. 4 All-oral DAA therapy offers cure rates exceeding 90% in compensated cirrhosis with a safe and short treatment course. 4
Recent data from a 5-year Japanese follow-up study showed that among patients with HCV-related cirrhosis who achieved SVR, the proportion with Child-Pugh A status increased from 12% at baseline to 40% at 5 years post-treatment. 5 The 5-year transplant-free survival rate was 91.5% for SVR patients compared to only 33.3% for virologic failure patients. 5
Most patients achieve SVR within 8-12 weeks of completing therapy, with the majority of Child-Pugh A patients achieving SVR in just 8 weeks. 6 A high degree of concordance exists between SVR12 and SVR24, meaning that undetectable HCV RNA at 12 weeks post-treatment reliably predicts long-term cure. 6